ESMO 19th World Congress on Gastrointestinal Cancer (19th WCGI)

Präsenzveranstaltung

Issues: Cancer of the Pancreas and Bile Ducts, Interpreting Clinical Trials Results, Esophageal and Gastric Cancers, Diseases and Cancers of the Liver, Inflammation, Genetics, NETs and HCC, Carcinoma of unknown origin a.m.m.

Presentation of selected abstracts Colorectal Cancer:

Impact in prognosis of circulating tumor DNA mutant allele fraction (MAF) in RAS mutant metastatic colorectal cancer (mCRC)
Enrique Sanz-García, et al. O-010

RET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC)
Filippo Pietrantonio, et al. O-011

Impact of prior bevacizumab treatment of VEGFA and PIGF levels and patient outcomes: A retrospective analysis of baseline plasma samples from the VELOUR trial
Eric Van Cutsem, et al. O-012

Presentation of selected abstracts New Drugs in GI Cancer and Abstracts on Non-Colorectal Cancer

Molecular variations between small bowel adenocarcinomas (SBAs), right-sided colon cancers (RT-Colon), and gastroesophageal cancers (GEC)
Mohamed Salem, et al., O-018

A phase Ib/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts)
Tanios Bekaii-Saab, et al., LBA-002

Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- Bevacizumab (bev) in metastatic colorectal cancer (mCRC) Patients (pts)
BH O’Neil, et al., LBA-003

Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC)
G. Argilés, et al., LBA-004

Venue:
CCIB in Barcelona, Spain